CT1812   Click here for help

GtoPdb Ligand ID: 13335

Synonyms: compiund 7 [PMID: 34531947] | CT-1812 | Elayta
Compound class: Synthetic organic
Comment: CT1812 is an orally bioactive, brain-penetrant sigma 2 (σ2) receptor complex allosteric antagonist [3]. In a phenotypic neuronal assay it reduced the synaptotoxic effects of amyloid β .oligomers. CT1812 was subsequently found to bind the σ2 receptor complex at the progesterone receptor membrane component 1 subunit and to displace amyloid β which is then disposed of via the cerebrospinal fluid [2]. In a transgenic mouse model of Alzheimer's disease CT1812 demonstrated some improvement in cognitive function.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 75.22
Molecular weight 431.59
XLogP 2.68
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CC(C)(C)OC1=CC(=CC=C1O)CCC(C)(C)N2CC3=CC=C(C=C3C2)S(=O)(=O)C
Isomeric SMILES CC(C)(C)OC1=C(C=CC(=C1)CCC(C)(C)N2CC3=C(C2)C=C(C=C3)S(=O)(=O)C)O
InChI InChI=1S/C24H33NO4S/c1-23(2,3)29-22-13-17(7-10-21(22)26)11-12-24(4,5)25-15-18-8-9-20(30(6,27)28)14-19(18)16-25/h7-10,13-14,26H,11-12,15-16H2,1-6H3
InChI Key ISQAPFMBJFZOLG-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
CT1812 is a clinical candidate for amyloid β dementias [1-2] and age-related macular degeneration.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05893537 Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD). Phase 2 Interventional Cognition Therapeutics
NCT05531656 A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease Phase 2 Interventional Cognition Therapeutics